Transcription of the human growth hormone (hGH) gene and its regulation are controlled by trans-acting factors that bind to hGH gene promoter sequences. Several DNase I footprints have been described within 500 bp of this promoter, one of which (-289 to -267) has not yet been ascribed to a defined factor. By DNase I footprinting, gel mobility shift, and methylation interference assays with extracts from HeLa cells and GH-producing pituitary tumor (GC) cells, we show that this factor belongs to the NF-I family. When NF-I was competed out of the cell extracts, the trans-acting factor AP-2 bound to the same site as NF-I. AP-2 was present not only in HeLa cells, but also in GC cells albeit at a much lower concentration. Consistent with the mutually exclusive binding of NF-I and AP-2, their methylation interference patterns included four guanine residues that were crucial for binding of both NF-I and AP-2. Cell-free transcription from the hGH gene promoter showed that these two factors ca... Several DNase I footprints have been described within 500 bp of this promoter, one of which (-289 to -267) has not yet been ascribed to a defined factor. By DNase I footprinting, gel mobility shift, and methylation interference assays with extracts from HeLa cells and GH-producing pituitary tumor (GC) cells, we show that this factor belongs to the NF-I family. When NF-I was competed out of the cell extracts, the trans-acting factor AP-2 bound to the same site as NF-1. AP-2 was present not only in HeLa cells, but also in GC cells albeit at a much lower concentration. Consistent with the mutually exclusive binding of NF-I and AP-2, their methylation interference patterns included four guanine residues that were crucial for binding of both NF-I and AP-2. Cell-free transcription from the hGH gene promoter showed that these two factors can transactivate this gene.
INTRODUCTION
The growth hormone (GH) gene is an interesting model for studying the control of gene expression by hormones and transacting factors. The human hGH-N (hGH-1) gene is expressed exclusively in the somatotrophs of the anterior pituitary. Its transcription is stimulated by GHRH via cAMP and by glucocorticoids (1) . The mechanism of these hormonal effects, which probably involve cis-acting hGH gene promoter sequences, is ill-understood. The tissue-specificity of expression of the hGH gene is ascribed, at least in part, to a pituitary-specific factor called GHF-1/Pit-I (2). This homeobox-containing protein (3) binds to two contiguous sites on the promoter, thereby protecting these sites against cleavage by deoxyribonuclease I (DNase I) (footprints -92 to -65 and -130 to -105).
Other factors, which also occur in nonpituitary cells such as HeLa cells, bind to the hGH gene promoter and may contribute to controlling its basal and (or) hormone-dependent transcription.
The interaction of some of these factors is revealed by the DNase I footprints observed on the hGH gene promoter when it is incubated with extracts from pituitary tumor (GC) cells or HeLa cells. One of these footprints, called growth hormone footprint 2 (GHF2), extends from -139 to -115 and is due to the binding of a factor indistinguishable from Spl (4) . Another footprint called GHF3 extends from -289 to -253. This footprint is due to factor(s) that appears to contribute to the control of hGH gene transcription (5) . While the proximal part of GHF3 (GHF3p, -266 to -253) reflects the binding of upstream stimulating factor/major late transcription factor (USF/MLTF) (4), the distal part of this footprint (GHF3d) has not yet been ascribed to a particular factor. Although activator protein 2 (AP-2) purified from HeLa cells had been reported (6) to bind on the hGH gene promoter from -287 to -265, we had shown (4) that GHF3d is probably due to another factor. We have now investigated this question by DNase I footprinting, gel mobility shift, and methylation interference assays. We have also evaluated the functional significance of factor(s) binding to GHF3d by cellfree transcription experiments. Binding assays DNase I footprinting and gel mobility shift assays were performed as described (4) . For the methylation interference assay, the procedure of Chodosh et al. (9) was used with minor modifications. Single stranded oligodeoxyribonucleotides were labeled with y-[32P]-ATP in the presence of T4 polynucleotide kinase and hybridized with the unlabeled complementary strand as described (4) . Probes were partially methylated with dimethylsulfate and used in a binding reaction, with the modification that each incubation was scaled up to 30 y1 and contained 50,000 cpm of the appropriate probe, 8 yg of poly(dIdC) and 120 yg of cell extract protein. For NF-I contact points analysis, all incubations also contained 50 ng (GC extracts) or 150 ng (HeLa extracts) of oligo AP-2 to prevent binding of this factor to the radioactive probe. For AP-2 contact points analysis, the incubation contained 100 ng of oligo NF-I to prevent binding of NF-I to the radioactive probe. After incubation at room temperature for 30 min, samples were loaded on a low ionic strength 5 % polyacrylamide gel and electrophorezed according to Carthew et al. (10) . Overnight autoradiography at 40 C identified free DNA (F) and bound protein-DNA complexes (B) which were isolated from the gel matrix by horizontal migration onto NA-45 DEAE membranes (Schleicher and Schuell). DNA was eluted as described (11) , phenol/chloroform extracted, and purified by anion exchange chromatography (Qiagen-tip 5). After two ethanol precipitations, the DNA was piperidine-cleaved, lyophilized, electrophorezed on a 18 % polyacrylamide-8 M urea gel, and visualized by autoradiography. (Table  1) shows that it contains two overlapping putative binding sites, one for AP-2 and one for nuclear factor I (NF-I). Each of these sequences contains one mismatch with the consensus. The AP-2 mismatch does not prevent binding of purified AP-2 (6). We therefore investigated whether NF-I can also bind to this region of the hGH gene promoter. NF-I actually refers to a family of ubiquitous nuclear proteins which are differently expressed depending on the tissue and species (12) . The footprints shown in Fig. 1 demonstrate that our cell extracts contained NF-I and that the latter can bind to the GHF3d sequence. The promoter of the LTR of MMTV known to contain a high affinity binding site for NF-I (13) was incubated with HeLa (lanes 2-5) or GC (lanes 6-9) cell extracts. A typical NF-I footprint was observed (lanes 2 and 6) at the expected coordinates, i.e. from -81 to -58 relative to the cap site. This NF-I binding was prevented by competing oligo GHF3d (lanes 3 and 7), but not by addition of two unrelated oligos such as AP-2 (lanes 4 and 8) or USF (lanes 5 and 9). We conclude that NF-I can recognize the GHF3d sequence despite the mismatch with the consensus.
MATERIALS AND METHODS
Gel mobility shift assays provided additional evidence for the binding of NF-I to the hGH gene promoter from -289 to -267. When labeled oligo GHF3d was incubated with HeLa or GC cell extracts a wide retarded band was observed, corresponding to protein-GHF3d interactions (Fig. 2 , lanes 2 and 5). A 50-fold molar excess of unlabeled oligo GHF3d inhibited the formation of this complex (lanes 3 and 6), which was therefore considered as specific. Indeed, an unrelated oligonucleotide (oligo USF) was unable to prevent the formation of this oligo GHF3d-protein complex (lanes 4 and 7). The width of this specific complex could reflect the polypeptidic heterogeneity of NF-I which generates closely migrating bands in gel mobility shift experiments (14) . The fact that this interaction persisted under high salt conditions (150 mM KCI) is also in favor of complexes involving NF-I (14, 15) . A qualitative difference was seen between the data obtained with HeLa and GC cell extracts. The specific complex produced in HeLa cell extracts migrated more slowly than the one produced in GC cell extracts (compare lanes 2 and 5 in Fig. 2 ). This is consistent with the different tissue and species expression of the polypeptides of the NF-I family, but does not rule out the involvement of unrelated proteins, since different factors can bind to a same DNA sequence (16) . We investigated this question by methylation interference experiments. Despite their heterogeneity, the members of the NF-I family share the same DNA binding domain (17, 18) and are therefore expected to produce the same methylation interference pattern on their specific DNA target. Double-stranded oligo GHF3d labeled at one 5' end was partially methylated with dimethylsulfate and used in a binding reaction with HeLa or GC cell extracts. Despite the difference seen in band shift between HeLa and GC cell extracts, the methylation interference pattern was identical with these two extracts (Fig. 3) . Data with the coding (Fig. 3A) and the noncoding (Fig. 3B ) strands show that the guanines that are essential for the interaction are located exclusively in the two boxes of the palindromic NF-I consensus sequence. On the coding strand and in the 5'half palindrome of the noncoding strand, these guanines correspond (Table 2) to those described to be crucial for the interaction between NF-I and its binding site on the adenovirus replication origin (19) . We conclude that polypeptides of the NF-I family present in HeLa and GC cell extracts interact with the same nucleotides of the sequence from -289 to -267 of the hGH gene promoter.
Mutually exclusive binding of NF-I and AP-2
To investigate the possible involvement of AP-2 in the GHF3d seen with GC incubation containing oligo NF-I (lane 6). The same pattern of specific complexes was obtained with these competing oligonucleotides in GC cell extracts (Fig. 4A) . These experiments suggest that the specific GHF3d-protein complex seen in our gel mobility shift assays results from an interaction with NF-I. The binding of AP-2 on the GHF3d sequence can be detected only when binding of NF-I is prevented. Thus, the binding of NF-I and AP-2 appears to be mutually exclusive in our experimental conditions. If the GHF3d footprint does correspond to the binding of either NF-I or AP-2, then the methylation interference pattern of the binding observed in absence of NF-I should involve the AP-2 consensus. The methylation pattern observed when NF-I was titrated out of the incubation (Fig. 5 and Table 2 ) was indeed clearly different from that detected by NF-I contact point analysis. Six of the seven guanines that were important for the interaction of the protein with the two DNA strands are part of the AP-2 consensus. The seventh guanine (noncoding strand) is just next to the 5' end of this consensus.
Gel mobility shifts with the isolated oligo GHF3d sequence do not necessarily reflect the situation with the intact promoter. Indeed, DNA-protein interactions may be influenced by flanking promoter sequences. To evaluate the actual contribution of NF-I and AP-2 to the GHF3d, we performed the DNase I footprinting experiments shown in Figure 6 . The expected GHF3 footprint was seen on the hGH gene promoter with the two cell extracts (lanes 2 and 6). To visualize only GHF3d, competing oligo USF was included (lanes 3-5, 7-9). When competing oligo AP-2 was added (lanes 3,7) the GHF3d footprint was not modified, as described earlier (4 
Functional studies
Cell-free transcription experiments were performed to determine how binding of NF-I or AP-2 affected the activity of the hGH gene promoter (Fig. 7) . The template used contained the so that effects of other factors can be more conveniently analyzed. The deletion Ai-260/-188 affects none of the footprints seen on the hGH gene promoter when incubated with GC or HeLa cell extracts. When transcribed in a GC cell extract, the construct generated transcripts initiated from around the cap site determined in vivo (21) , namely at nucleotides + 1 and +2. These transcripts were RNA polymerase II-dependent since they disappeared in presence of ct-amanitin (not shown). When the experiment was conducted in presence of competing oligo NF-I, there was a 40% decrease in transcriptional activity. Because the template DNA/protein ratio is much higher in cell-free transcription than in binding assays, AP-2 was expected to interact with the templates even in the presence of NF-I. Indeed, addition of competing oligo AP-2 led to a decrease of 30% in transcriptional activity. One would therefore predict that transcriptional activity is further decreased in presence of a mixture of competing oligo NF-I and AP-2. Data in Fig. 7 show that this was the case since transcription was now reduced by about 50%. We conclude that NF-I and AP-2 both can trans-activate the hGH gene promoter. The residual transcriptional activity observed under these conditions may be ascribed to untitrated factors, including USF/MLTF which is known to bind to this construct (4).
DISCUSSION
We have studied here the cell-free binding of transcription factors to the hGH gene promoter sequence from -289 to -267 (GHF3d), the only footprint within 0.5 kb of this promoter which
has not yet been ascribed to a defined factor. By DNase I footprinting and gel mobility shift assay, we have shown that this sequence can bind Nuclear Factor I (NF-I)/CCAAT Transcription Factor (CTF) in a specific way. NF-I and CTF have been independently described but actually refer to the same family of factors (14) . NF-I was originally purified from HeLa cells as a DNA-binding protein required for efficient adenovirus replication in vitro and in vivo (14, 15) . CTF was known for its ability to activate several eukaryotic promoters (14) . Using methylation interference, de Vries et al. (19) ?.
the DNA bases shown in Table 2 . This raised the question of the actual contact points of NF-I with an eukaryotic promoter such as that of the hGH gene. The five guanines that are involved in the interaction of NF-I with the adenovirus sequence (19) were found here as being important also in the hGH gene sequence ( Table 2) . Methylation of a guanine on the hGH gene noncoding strand (-282) prevented NF-I binding. This guanine corresponds to a thymine (+28) on the noncoding strand of the adenovirus sequence. Thus, replacement of this adenovirus pyrimidine by a purine does not prevent NF-I binding, and this confirms BrdUsubstitution data (19) . In contrast, methylation of the guanine at position -281 on the noncoding strand did not interfere with NF-I binding to the hGH gene sequence, despite the fact that methylation of the corresponding adenine at position +29 of the adenovirus did (Table 2 ). This is consistent with the fact that dimethylsulfate methylates guanines on the N7 atom which is in the major groove and adenines on the N3 atom which is in the minor groove of the DNA helix. This confirms that NF-I faces the minor groove at coordinate +29 of the adenovirus and suggests that it is also the case at coordinate -281 of the hGH gene promoter. The guanines at -272 and -277 on the coding strand of the hGH gene sequence replace the adenines at +38 and +33 of the adenovirus sequence. Methylation of these guanines did not interfere with NF-I binding. The electrophoretic mobilities of the complexes between NF-I and its target sequence differed depending on the origin of this factor i.e. HeLa or GC cells (Fig. 2) , and yet the methylation pattern was identical (Fig.  3) . This is compatible with the finding (12, 17, 18 ) that different tissues may express different isoforms of NF-I all sharing the same DNA binding domain. We conclude from these experiments that the molecular mechanisms of DNA recognition by NF-I are similar when this factor binds to the origin of replication of adenovirus and to the hGH gene promoter. This is consistent with the recent finding that the same domain of NF-I mediates DNA binding on the adenovirus origin of replication and on an eukaryotic promoter (22) . AP-2 purified from HeLa cells protects two regions of the hGH gene promoter against cleavage by DNase I (6). The first region (-167 to -145) binds AP-2 with low affinity and the other (-287 to -265), which corresponds approximately to GHF3d (-289 to -267), binds AP-2 with much higher affinity. However, with crude HeLa cell extracts, no footprint was seen at the low affinity site (5) and we show here with such extracts that the footprint located at the high affinity site is in fact due to NF-I. When the latter was titrated out of these cell extracts, AP-2 did produce an identical footprint, consistent with the mutually exclusive binding of AP-2 and NF-I to this site. By gel mobility shift assay, we have demonstrated that AP-2 is also present in GC cell extracts, but at a much lower concentration than in HeLa cell extracts. Indeed, no AP-2 footprint was seen from -289 to -267 when NF-I was titrated out of GC cell extracts. Methylation interference experiments showed that six guanines that were important for the interaction of AP-2 with the two DNA strands are part of the AP-2 consensus. Our identification of a crucial guanine residue just next to the AP-2 consensus is not surprising since the length of this consensus varies from 8 to 10 bp (20, 6) . Our data also show that methylation of four guanine residues, namely at -276 and -283 on the coding strand and -275 and -282 on the noncoding strand, prevented binding of both NF-I and AP-2. This supports the mutually exclusive character of the binding of these factors on the hGH gene promoter. There are other cases where AP-2 or a CCAAT-transcription factor is displaced by another protein.
A CCAAT-binding transcription factor that interacts with a sea urchin histone 2B-1 gene promoter is competed for by a spermspecific CCAAT displacement protein which might act as a repressor of gene transcription (23) . Another example is the displacement of AP-2 by AP-3 from its binding site on the SV40 core sequence (24) .
As to the functional significance of NF-I binding, our cell-free transcription data suggest that this factor stimulates transcription from the hGH gene promoter. This interpretation is in agreement with transfection data from Lefevre et al. (5) . One of their hGH gene promoter mutants called ANco2-CAT that lacked a region encompassing the GHF3d sequence was less active in terms of CAT activity than the intact promoter. Moreover, two other hGH gene promoter mutants (hGH-NK and hGH ANcol) that had an altered GHF3d sequence, and yet still showed a footprint, were as active as the intact promoter in the CAT assay. This behavior can now be explained in light of our results since these mutants still contain a NF-I consensus. NF-I is also known to be involved in the glucocorticoid-dependent stimulation of transcription from the MMTV promoter (25, 26) . Schule et al. (27) and Strahle et al. (28) showed that NF-I can interact synergistically with the glucocorticoid receptor to stimulate MMTV transcription. Since this receptor also binds to the hGH gene (29, 30) , NF-I could play a similar role in controlling glucocorticoid-dependent transcription of this gene. Concerning AP-2, this relatively cellspecific factor is involved in the basal control of promoters such as that of the metallothionein-IIA gene where it mediates transcriptional activation by phorbol esters and cAMP (6) . A role of AP-2 in the cAMP-dependent transcriptional activation of the hGH gene by GHRH was therefore an interesting possibility. However, this hypothesis has been recently discounted by experiments with hGH gene promoter deletion constructs (31) . Still, our cell-free transcription experiments suggest that AP-2 can trans-activate the hGH gene, which is therefore a candidate for regulation by this factor in vivo. Transcription of the rat GH gene is stimulated by retinoic acid through 5' flanking cis-acting sequences (32) . Since retinoic acid increases the concentration of AP-2 mRNA (33), a role of AP-2 in this control mechanism cannot be excluded.
The cloning of NF-I and AP-2 has shown that their DNAbinding domains share no structural features with each other or with other trans-acting factors (22) . However, NF-I and AP-2 have in common a proline-rich domain which appears to be indispensable for their transcriptional activity (22) . Since NF-I and AP-2 can trans-activate the hGH gene by binding to the same promoter region, the interaction of this proline-rich domain with a specific component of the transcriptional machinery might involve a trans-activating mechanism that is common to NF-I and AP-2.
